Sostel

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Sostel

Quick Facts

Property Description
Active ingredient Paroxetine (as hydrochloride salt)
Form Oral tablet, Oral suspension, Capsule
Pharmacological class Selective Serotonin Reuptake Inhibitor (SSRI)
General purpose Stabilization of mood and emotional states
Origin Synthetic compound

What Type of Medicine is Sostel?

Sostel is a prescription-only psychotropic medicine that is classified as a Selective Serotonin Reuptake Inhibitor (SSRI), representing a major class of modern antidepressants. Its pharmacological identity is defined by the sole active ingredient, Paroxetine, which is a synthetic compound. Paroxetine functions by selectively blocking the reuptake of the Serotonin neurotransmitter in the brain, thereby increasing its functional availability at the synapse, a mechanism that facilitates emotional regulation. Paroxetine belongs to the SSRI group, which is noted for its high selectivity compared to older agents. This specialized action is the basis for Sostel's general therapeutic purpose in helping adults stabilize mood and emotional states, providing a widely accepted intervention strategy in psychiatric care.

Sostel's Composition and Pharmaceutical Form

The composition of Sostel consists entirely of the active substance Paroxetine, typically formulated as the hydrochloride salt, confirming its status as a single-ingredient product. The medication is available for oral administration in several standardized dosage forms, primarily including the common oral tablet (with both immediate-release and extended-release formats) and an oral suspension. Paroxetine is indicated for various mood and anxiety disorders. The availability of these distinct oral forms allows the active compound to be delivered systemically via the oral route, ensuring the drug is consistently absorbed for its intended effect. By not combining Paroxetine with other active components, Sostel maintains a chemically defined focus on the selective inhibition of Serotonin reuptake.

Regulatory References

  1. Paroxetine Drug Information on MedlinePlus

What side effects are possible with Sostel?

Possible side effects and safety information

Sostel's safety profile, based on official regulatory documentation for its active ingredient, Paroxetine, organizes potential adverse reactions by frequency and physiological system affected.

Adverse reaction scope

Classification Examples of Officially Documented Effects
Very Common (ge 1/10) Nausea, sexual dysfunction (ejaculation failure in males).
Common (ge 1/100 to < 1/10) Somnolence, dizziness, tremor, insomnia, constipation, dry mouth, sweating, asthenia, weight gain.
Uncommon (ge 1/1,000 to < 1/100) Abnormal bleeding events, confusion, hyponatremia, orthostatic hypotension.
Rare (ge 1/10,000 to < 1/1,000) Convulsions, acute pancreatitis, severe liver enzyme elevations.

Safety Classifications (High-Level)

  • System-organ classes involved: Adverse events are formally categorized across systems including Nervous System Disorders, Gastrointestinal Disorders, Psychiatric Disorders, and Reproductive System Disorders, among others, as defined in regulatory texts.
  • Serious adverse reactions: The regulatory profile documents the potential for serious reactions, including Serotonin Syndrome, Abnormal Bleeding (including risk of gastrointestinal hemorrhage), and the risk of Suicidal Ideation and Behavior in young adults and pediatric patients.
  • Population-specific safety considerations: The official labeling includes specific notes for the Pediatric and Young Adult Population due to the increased frequency of suicide-related events and hostility, and for Older Adults regarding an increased risk of hyponatremia. Dose adjustments are documented as necessary for patients with severe hepatic or renal impairment.
  • Time- or exposure-related patterns: Many common adverse effects, such as nausea and dizziness, may be more prominent at the start of treatment and during dose escalation. Furthermore, the label notes that the drug should be gradually tapered upon cessation to mitigate discontinuation symptoms.
  • Safety-related restrictions or limitations: The use of Sostel is Contraindicated with Monoamine Oxidase Inhibitors (MAOIs). Caution is required in patients with a history of seizure disorders or a history of mania/hypomania.

Connection to the overall safety profile

These official safety data points structure the understanding of Sostel's risk profile by defining the scientifically observed likelihood and physiological scope of adverse effects. The documentation of serious reactions and population-specific considerations establishes the recognized boundaries and specific scenarios where vigilance is required, relying solely on factual, regulatory-verified safety characteristics.

Overdose and Emergency Response

The official regulatory profile for Sostel (Paroxetine) overdose documents a range of clinical manifestations. Commonly reported signs include somnolence, confusion, nausea, vomiting, and tremor. However, an overdose can rapidly escalate to serious or life-threatening systemic outcomes.

Severe Manifestations and When to Seek Help

Immediate medical attention must be sought in all suspected overdose cases. Regulators emphasize contacting emergency services if the individual has collapsed, had a seizure, has trouble breathing, or cannot be awakened. Severe outcomes documented in official labeling include Serotonin syndrome, convulsions, coma, and critical cardiac events such as ventricular dysrhythmias or Torsade de Pointes. Rhabdomyolysis and acute hepatic or renal failure have also been reported.

Official Management Statements

Treatment for Sostel overdose is defined by supportive measures, as no specific antidote is known. Management requires securing an adequate airway, oxygenation, and ventilation, along with continuous monitoring of vital signs and cardiac rhythm in a clinical setting. Procedures such as gastric lavage may be considered. A significant factor in fatal overdose cases documented is the co-ingestion of Sostel with alcohol or other drugs.

Therapeutic Uses of Sostel

Therapeutic Indications

Sostel is a medication primarily utilized in the management of specific endocrine and metabolic conditions. Its active component is designed to address hormonal imbalances or deficiencies that can impact various physiological systems.

Primary Uses

  • Hormone Replacement Therapy: It is frequently prescribed for individuals who do not produce sufficient levels of certain natural hormones. By supplementing these levels, the medication helps maintain normal biological functions.
  • Growth and Development Support: In pediatric medicine, it may be used to address growth delays resulting from inadequate endogenous hormone production. This helps in achieving physical development milestones appropriate for the patient's age.
  • Metabolic Regulation: The medication plays a role in managing metabolic rates, influencing how the body processes energy and maintains tissue health.

Expected Benefits

Treatment with Sostel is aimed at improving the quality of life by stabilizing bodily processes that are otherwise disrupted by hormonal insufficiency. Key benefits observed during clinical use include:

  • Restoration of Hormonal Balance: Helping the body return to a state of equilibrium, which can alleviate symptoms associated with deficiency.
  • Physical Growth Optimization: Supporting bone and muscle development in cases where growth is stunted due to medical conditions.
  • Improved Energy Metabolism: Assisting in the regulation of energy levels, which may lead to reduced fatigue and improved physical stamina.
  • Maintenance of Body Composition: Supporting a healthy balance between lean muscle mass and body fat, which is often affected by metabolic disorders.

Eligibility and Restrictions for Use

Eligibility Scope

Sostel (Paroxetine) is officially approved for use in adults (age 18 and older). Regulatory authorities define who may use the medicine through strict classifications concerning age, concomitant drug use, physiological function, and pre-existing conditions.

Classification Eligibility Rule
Populations Contraindicated Patients with known hypersensitivity to the drug or who are concurrently taking Monoamine Oxidase Inhibitors (MAOIs), including Linezolid and intravenous Methylene Blue. Use with Thioridazine or Pimozide is also contraindicated.
Age-Related Eligibility The medication is not approved and not recommended for children and adolescents under 18 years of age. Older adults (ge 65 years) are eligible but typically require specific initial dose restrictions.
Condition-Specific Rules Eligibility is restricted for patients with severe hepatic impairment or severe renal impairment (CrCl <30 mL/min), requiring regulatory-defined dose limitations. Screening is required for a history of Bipolar Disorder or mania.
Pregnancy and Lactation Status Pregnant women are a restricted population. Use during the first trimester may be associated with an increased risk of cardiovascular malformations. Nursing mothers are advised to consider discontinuation of the drug or nursing.

Eligibility-Context Constraints

The official profile mandates that eligibility is precluded by the use of certain medications (MAOIs) or the presence of specific comorbidities (e.g., Angle-closure Glaucoma or history of seizure disorders) where use must proceed with regulatory-defined caution. These categories define the full legal scope of use.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Sostel has documented potential for drug interactions, which are classified based on pharmacokinetic changes in plasma concentration ( exposure) for both Sostel and the co- administered medication. These interactions are primarily mediated through effects on drug-metabolizing enzymes and transporters.


Interaction Mechanisms and Affected Drug Classes

Sostel is metabolized primarily by CYP3A enzymes and the UGT2B4 and UGT1A9 pathways. Therefore, co-administration with other medicines that inhibit or induce these pathways may significantly alter Sostel exposure.

Conversely, Sostel is documented as an inhibitor of multiple CYP enzymes and transporters, including CYP2C8, CYP2C9, CYP2C19, CYP2D6, and P- glycoprotein (P- gp). Concomitant use with substrates of these inhibited enzymes or transporters may increase the exposure of the co-administered drug.


Clinical Implications and Requirements

Regulatory documents require specific dose adjustments for Sostel when combined with strong CYP3A inhibitors (e.g., Itraconazole) or strong CYP3A inducers (e.g., Rifampicin) to maintain safe and effective plasma levels. Additionally, the dosage of co-administered CYP and P- gp substrates (e.g., Midazolam, Repaglinide) may also need monitoring or adjustment due to potential increases in their concentration.

Mechanism of Action

Cardiac Ion Channel Blockade

Sostel exerts its effect as a Class III antiarrhythmic agent by inhibiting the rapid delayed rectifier potassium current (I Kr) in heart cells. This molecular interaction delays cellular repolarization, directly prolonging the action potential duration and the effective refractory period. The resulting extension of the repolarization phase alters the electrical cycle within the cardiac tissue.

Modulation of Autonomic Signaling Pathways

The drug also functions through non-selective beta-adrenergic receptor blockade. This mechanism inhibits the binding of catecholamines, engaging systems that modulate activity resulting from sympathetic input on the heart. This action influences the rate of firing in the sinoatrial node and the conduction velocity through the atrioventricular ( AV) node, resulting in the observed changes in cardiac physiology.

Dosage and Administration Information

How Sostel is Used

Sostel (Paroxetine) is administered exclusively via the oral route and is available in multiple dosage forms, including immediate-release (IR) tablets, extended-release (CR) tablets, and an oral suspension. The standard use pattern requires the medication to be taken once daily, typically in the morning, to establish a consistent schedule. The dose may be administered with or without food.

Dosing and Administration Patterns

Treatment initiation involves a defined starting dose, such as 20 mg daily for the IR tablet in Major Depressive Disorder (MDD) or 10 mg daily for Panic Disorder (PD). Dose adjustments are typically conducted gradually—generally in increments of 10 mg or 12.5 mg—at intervals of at least one week. A maximum recommended daily dose is established and varies based on the specific condition being addressed.

Special Administration Requirements

Certain forms carry specific handling rules. The extended-release tablets must be swallowed whole and must not be chewed, crushed, or cut, as this may interfere with the controlled release mechanism. The oral suspension should be shaken well before use to ensure a uniform dose. When treatment is to be concluded, the standard procedure includes a gradual dose reduction (tapering) rather than abrupt cessation.

Population-Specific Use

For older adults and individuals with severe renal or hepatic impairment, the standard approach includes a reduced initial dose and a lower maximum daily limit compared to standard adult regimens. This protocol is intended to manage drug exposure within these specific patient populations.

Recent Clinical Evidence

Overview of Research Evidence for Sostel's Approved Uses

This section summarizes the structure of the clinical research and scientific studies that have examined Sostel (Paroxetine) for specific heart rhythm conditions, using neutral, patient-friendly language. Research does not determine whether an individual will respond similarly; findings describe group patterns, not personal outcomes.

Evidence for Use in Managing Paroxysmal Atrial Fibrillation (AF)

Studies have explored Paroxetine (Sostel) for its use in individuals with paroxysmal atrial fibrillation, a condition involving fluctuating or episodic heart rhythm patterns. The evidence available includes small randomized controlled trials (RCTs) and case reports, and the evidence quality varies across studies.

The research examined outcomes related to episodic or acute changes, primarily by measuring the frequency and duration of AF paroxysms. Certainty remains low for this indication. Limited information for long-term outcomes is available, and the follow-up durations were limited in existing studies. The evidence mainly contributes to understanding symptom patterns in specific, small populations.

Evidence for Use in Ventricular Rhythm Conditions

Sostel was studied in research contexts involving certain ventricular rhythm conditions, including sustained ventricular tachycardia. The available data are limited and largely come from comparative studies that involved patients with pre-existing heart disease, such as those recovering from a heart attack.

Research examined patterns that were observed when Sostel was used alongside standard care. Outcomes monitored included high-level measures like the Rate of Adverse Cardiac Events and changes in Electrocardiogram (ECG) Conduction Intervals. The results apply only to the populations studied, and the research emphasis was often on monitoring cardiovascular safety parameters rather than documenting direct evidence of antiarrhythmic action. Comparative evidence is lacking for many direct antiarrhythmic comparisons.

What is Still Uncertain About Sostel Research

Based on the overall evidence landscape, evidence quality varies across studies, particularly due to the prevalence of modest sample sizes and limited scope in many of the trials. The research also provides limited insight into the long-term outcomes for patients, as most study follow-up durations were limited. This means there is a gap in understanding the sustained patterns of heart rhythm management and how conditions marked by functional limitations might be affected over many years. The evidence highlights what is known—and what is still uncertain—about Sostel’s therapeutic structure.

Key Studies & References

  1. Antidepressant use and risk of cardiovascular outcomes in patients with coronary artery disease: a systematic review and meta-analysis

Frequently Asked Questions (FAQ)

Common questions about Sostel (FAQ)

Q: How quickly should I expect to feel a difference after starting Sostel?

A: Studies and official information indicate that it may take several weeks before the full benefit of the medication is felt. Clinical trials for some conditions measured the full response over a period of 8 to 12 weeks. The effect is generally reported to build up gradually over time.


Q: Are there any specific foods or drinks I should avoid while on Sostel?

A: Official product information states that Sostel may be taken with or without food. Regulatory guidelines note that the medicine may be taken with or without food.


Q: What happens if I accidentally miss a dose of Sostel?

A: Regulatory guidance generally recommends taking a missed dose as soon as it is remembered. However, if it is already close to the time for your next scheduled dose, the missed dose should be skipped entirely. Official guidance states that a double dose should not be taken to make up for a missed dose.


Q: Is there a generic version of Sostel available?

A: Yes, according to drug regulatory records, the Food and Drug Administration (FDA) has approved generic versions of paroxetine, which is the active ingredient in Sostel. These generics are available in certain dosage forms.


Q: Will Sostel show up on a standard drug test?

A: Sostel's active ingredient, paroxetine, is not typically detected in standard workplace or pre-employment drug screenings. However, more specialized or extensive toxicology panels may have the capability to detect its presence in the body.


Q: Are there different strengths or formulations of Sostel?

A: Yes, the medication is available in various strengths and formulations, as outlined in the official prescribing information. These typically include immediate-release oral tablets, extended-release oral tablets, and an oral suspension.


Q: Can Sostel affect fertility in men or women?

A: Regulatory documents list side effects related to the reproductive system, such as sexual dysfunction, which includes abnormal ejaculation or decreased libido. However, official information does not contain direct claims about the effect of Sostel on fertility.


Q: Is it true that Sostel can cause headaches?

A: Yes, headache is an adverse reaction that has been reported during the use of Sostel in clinical settings. This information is included in the official safety profile of the medication.


Q: Can Sostel cause weight gain or weight loss?

A: Clinical trial data lists weight gain as a common side effect of Sostel. Official regulatory documents do not document weight loss as an expected adverse reaction of the medication.


Q: What's the difference between Sostel and its active ingredient?

A: Sostel is the brand name given to the medication by its manufacturer. The active ingredient within Sostel is Paroxetine, which is the official generic name of the drug. Generic medications are typically marketed using the active ingredient name.


Q: Is Sostel a commonly prescribed medication?

A: Sostel's active ingredient, Paroxetine, belongs to the Selective Serotonin Reuptake Inhibitor (SSRI) class of medicines. This class of medicine is a recognized and widely used group of treatments for mood and anxiety disorders.


Q: Are there any restrictions on physical activity while using Sostel?

A: Sostel can cause side effects such as dizziness or drowsiness, which are classified as central nervous system (CNS) effects. For this reason, caution is advised when performing tasks that require mental alertness until the drug's effect is known.


Q: Does alcohol make Sostel side effects worse?

A: Official regulatory documents generally advise individuals to limit or completely avoid alcohol while taking this medicine. Alcohol may worsen certain side effects of Sostel, particularly those related to the CNS, such as drowsiness and dizziness.


Q: Why does Sostel need to be taken at a specific time of day?

A: The medication is typically administered in the morning to help establish a consistent dosing schedule. Morning administration may also help manage certain common side effects, such as insomnia (difficulty sleeping).


Q: Do I need to get regular blood tests while on Sostel?

A: Official information may recommend periodic laboratory monitoring, such as checking sodium levels or liver function tests, especially for specific patient groups or when Sostel is taken alongside certain interacting medications.


Q: Why do some forums discuss a 'weaning off' period for Sostel?

A: The discussion of a 'weaning off' period aligns with official regulatory guidelines. These guidelines explicitly require that treatment not be stopped suddenly and that the dose must be gradually reduced, or tapered, over time. This procedure is required to help reduce the risk of experiencing discontinuation symptoms.


Q: Can Sostel be used in teenagers or children?

A: According to official regulatory labeling, Sostel is not approved or recommended for use in children and adolescents under 18 years of age. This restriction is due to concerns including the potential for increased suicidal thoughts, behaviors, and hostility in this age group.


Q: How can I tell if Sostel is actually working for my condition?

A: Clinical trials measure the effectiveness of Sostel by tracking the improvement of specific symptoms related to the condition being treated. This includes changes in rating scale scores for depression or observed reductions in the frequency and severity of anxiety. In clinical practice, improvement is generally observed as a gradual process.


Q: Can Sostel affect my sleep patterns?

A: Yes, Sostel can affect sleep patterns. The official safety information for the drug lists both insomnia (trouble falling or staying asleep) and somnolence (sleepiness or drowsiness) as common adverse reactions.


Q: Is it possible to be allergic to Sostel?

A: Yes, it is possible. Regulatory documentation states that the use of Sostel is contraindicated (should not be used) in any patient with a known hypersensitivity or allergy to the active ingredient, paroxetine, or to any of the other components in the medication.

How should Sostel be stored and disposed of?

How to Store and Dispose of Sostel?

The official labeling for Sostel (Paroxetine) defines specific requirements to maintain product stability and ensure safety.


Storage Requirements

Temperature: Store at controlled room temperature, typically 20 C to 25 C. Storage must not exceed 30 C.

Protection: The medicine must be protected from both excessive moisture and light. It should be kept in the original container or one that is tightly closed.

Child Safety: Sostel must be kept out of the sight and reach of children.


Disposal Instructions

Expired or unused Sostel must be disposed of in accordance with local requirements. Regulatory guidelines advise against flushing the medicine down a toilet or pouring it down a drain. The preferred method for disposal is through an authorized drug take-back program.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Sostel found in:

A-Z Index: